The votes are in. Here are your choices for best and worst CEOs
(HYACINTH EMPINADO/STAT)
One executed on a years-long plan to bring new medicines to patients with a devastating disease. The other presided over a $60 billion loss in value.
They are, respectfully, your choices for the best and worst CEOs in biopharma, as curated by STAT’s Adam Feuerstein. The voting was close on the best side, where a once-doubted, recently vindicated executive nearly prevailed. But it was a runaway when it came to the worst, perhaps because $60 billion is a lot of dollars.
Read more about the winners here, and start making your list for 2019.
They are, respectfully, your choices for the best and worst CEOs in biopharma, as curated by STAT’s Adam Feuerstein. The voting was close on the best side, where a once-doubted, recently vindicated executive nearly prevailed. But it was a runaway when it came to the worst, perhaps because $60 billion is a lot of dollars.
Read more about the winners here, and start making your list for 2019.
.png)
No hay comentarios:
Publicar un comentario